ReportAlert.info - Baxter (NYSE:BAX) publishes 2010 Sustainability Report
(3BL Media / theCSRfeed) July 5, 2011 - Baxter International Inc. released its 2010 Sustainability Report, available at http://www.reportalert.info/ra/profiles/Baxter/2011/?ID=39449, marking the 12th consecutive year the company has released a report about its social, economic and environmental performance. The report, which is aligned with the Global Reporting Initiative guidelines, features progress toward the company’s sustainability priorities and goals and its commitment to addressing global sustainability challenges through a range of initiatives.
Initiatives highlighted in the 2010 report include:
- Decreasing water use by 10 percent in absolute terms and 31 percent indexed to revenue compared to 2005, exceeding Baxter’s 2010 water-reduction goal of 20 percent indexed to revenue.
- Decreasing net greenhouse gas (GHG) emissions from operations by 7 percent in absolute terms and 29 percent indexed to revenue compared to 2005, exceeding its GHG-reduction goal of 20 percent indexed to revenue.
- Providing nearly $80 million in company cash contributions, product donations and grants from The Baxter International Foundation to address critical global needs.
Baxter's sustainability priorities reflect issues of key concern to Baxter and its stakeholders and areas where the company is uniquely positioned to have a positive impact. Long-term performance goals aligned with each priority provide measurable targets and help assess performance. Baxter’s sustainability priorities include creating an inclusive workplace, strengthening access to healthcare, and a range of environmental initiatives such as reducing GHG emissions, waste generation and water usage.
Stakeholder feedback is an important source of ideas for continual improvement. Please provide comments or suggestions through Baxter’s online survey at http://www.zoomerang.com/Survey/WEB22CGRTP54TY/
Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.